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Abstract
Background: The antibacterial activity of bacteriophages has been described rather well. However, knowledge
about the direct interactions of bacteriophages with mammalian organisms and their other, i.e. non-antibacterial,
activities in mammalian systems is quite scarce. It must be emphasised that bacteriophages are natural parasites
of bacteria, which in turn are parasites or symbionts of mammals (including humans). Bacteriophages are
constantly present in mammalian bodies and the environment in great amounts. On the other hand, the
perspective of the possible use of bacteriophage preparations for antibacterial therapies in cancer patients
generates a substantial need to investigate the effects of phages on cancer processes.
Results: In these studies the migration of human and mouse melanoma on fibronectin was inhibited by purified
T4 and HAP1 bacteriophage preparations. The migration of human melanoma was also inhibited by the HAP1
phage preparation on matrigel. No response of either melanoma cell line to lipopolysaccharide was observed.
Therefore the effect of the phage preparations cannot be attributed to lipopolysaccharide. No differences in the
effects of T4 and HAP1 on melanoma migration were observed.
Conclusion:  We believe that these observations are of importance for any further attempts to use
bacteriophage preparations in antibacterial treatment. The risk of antibiotic-resistant hospital infections strongly
affects cancer patients and these results suggest the possibility of beneficial phage treatment. We also believe that
they will contribute to the general understanding of bacteriophage biology, as bacteriophages, extremely
ubiquitous entities, are in permanent contact with human organisms.
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Background
Melanoma and other skin cancers are still among the most
serious public health problems. According to the World
Health Organization, more than 210,000 skin cancer
cases occur every year and about 66,000 patients die as a
result. Skin cancers mostly affect humans with light skin;
the mortality ratio per 100,000 persons per year is highest
in Australia and New Zealand (7.6–7.8), in Europe (1.6–
6.4), and in Canada and the United States (3.3–3.8) [1].
This type of cancer is usually characterised with high met-
astatic activity and relatively high fatality. Besides the con-
stantly emphasised role of early recognition and
prevention, surgical removal of tumour and chemother-
apy constitute the standard treatment [2]. Surgical proce-
dures and hospital treatment expose cancer patients to a
high level of hospital bacterial infections. The risk of hos-
pital bacterial infection is substantial. According to the
World Health Organization, between 5% and 10% of
patients admitted to hospitals in industrial countries and
more than 25% of those in developing countries acquire
such infections. This means hundreds of millions of hos-
pital infections every year and a substantial death rate [3].
"Hospital" strains of bacteria are the main representatives
of antibiotic-resistant, often multi-drug-resistant, micro-
organisms. Bacteria are particularly efficient in developing
resistance because of their ability to multiply very rapidly
and because they can easily transfer their resistance genes
(by normal replication and conjugation). Hospitals are a
critical component of the antimicrobial resistance prob-
lem worldwide. This results from the combination of
highly susceptible patients, intensive and prolonged anti-
microbial use, and easy cross-infection [4].
Bacteriophages, bacterial viruses unable to infect eukaryo-
tic cells, constitute a serious alternative to antibiotic ther-
apy of bacterial infections [5]. These viruses have been
known for almost a hundred years, but renewed interest
was noted as the crisis of antibiotic resistance in bacteria
became serious. Although phage therapy is limited to only
a few therapeutic centres worldwide, the available data
documents its high effectiveness and safety. Complete
independence from antibiotics' antimicrobial mecha-
nisms was also shown, i.e. bacteriophages do not follow
antibiotics' cross-resistance and can be fully effective on
antibiotic-resistant bacterial strains [6-9].
The antibacterial activity of bacteriophages has been
described rather well and its molecular mechanisms and
qualifying agents are also well known. However, knowl-
edge about the direct interactions of bacteriophages with
mammalian organisms and their other (i.e. non-antibac-
terial) activities in mammalian systems is quite scarce. As
bacteriophages are unable to infect mammalian cells, they
are considered a neutral object characterised by their anti-
genic properties [10]. It must be emphasised that bacteri-
ophages are natural parasites of bacteria, which in turn are
parasites or symbionts of mammals (including humans).
This implies a role of mammalian organisms as a special
environment for bacteriophages' life cycles. One should
expect that bacteriophages adapt to this special "environ-
ment" and develop the means of interacting with it. It is
known that some phages are more effective in escaping
mammalian immune system [11]. These interactions may
affect various aspects of immunological and physiological
processes and may potentially be advantageous or disad-
vantageous. Importantly, the possiblebacteriophage circu-
lation in the mammalian body may have a role in the
body's defences. Recent findings suggest that bacteri-
ophages may modulate immune functions [12]. These
open new perspectives for the understanding of bacteri-
ophage biology and for the development of bacteriophage
therapies.
The perspective of the possible use of bacteriophage prep-
arations in cancer patients generates a substantial need to
investigate the effects of phages on cancer processes. Inter-
estingly, antimetastatic activity and some inhibition of
tumour with T4-like (T4, T2, HAP1) bacteriophage prepa-
rations were observed in mice [13,14]. A hypothesis [15]
for this unexpected phage activity was proposed with
respect to the action of a KGD (Lys-Gly-Asp) amino-acid
motif present in gp24 of the T4 phage capsid. KGD is a
homologue of the RGD motif which is known to block the
activity of beta-3 integrin function in cancer cells. RGD
and its homologues are also known disintegrins for
alpha(5)beta(1) integrins [16,17]. Both beta-3 integrins,
i.e. alpha(v)beta(3) and alpha(IIb)beta(3), and
alpha(5)beta(1) mediate cancer cell motility and adhe-
sion and usually promote metastasis and malignancy.
They are expressed at high levels in melanoma cells, in
contrast to normal melanocytes. Direct engagement in
adhesion processes, interactions with extracellular matrix
(ECM), and modulation of matrixmetallo-proteinase
(MMP) activity in melanoma cells make these integrins
among the most important factors mediating melanoma
migration [18,19].
Here we report our observations of the effect of T4-like
phages on human (Hs294T) and mouse (B16) melanoma
migration in vitro. The study was intended to provide fur-
ther necessary data on bacteriophages' activity in cancer
processes and to verify previous observations. The in vivo
anticancer effects of bacteriophages may result from an
impact of the investigated preparations on immunologi-
cal systems (which has to be seriously considered) or from
direct interactions with cancer cells. In vitro migration
excludes the effect of complex mammalian immunology.
As T4-like phages are coliphages, their preparations con-
tain lipopolysaccharide (LPS); even highly purified prep-
arations contain a residual amount of LPS [20]. LPS is aBMC Microbiology 2009, 9:13 http://www.biomedcentral.com/1471-2180/9/13
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potent activator of various processes in mammalian cells.
These considerations make studies of the effects of LPS on
melanoma migration indispensable. Therefore we investi-
gated its potential effect in all the experiments conducted
with bacteriophages, constituting a control for the studies
of the bacteriophages themselves.
Methods
Bacteriophages
T4 phage was purchased from American Type Culture Col-
lection (ATCC) (Rockville, Maryland, USA). HAP1 (a T4
sub-strain with a high affinity to melanoma cells) was
selected at our institute: the Institute of Immunology and
Experimental Therapy, Polish Academy of Sciences, Wro-
claw (IIET) [13]. The bacteriophages were cultured with
Escherichia coli B from the Collection of Microorganisms at
the IIET. The material comprised highly purified prepara-
tions of bacteriophages T4 and HAP1. The bacteriophages
were purified by filtration through polysulfone mem-
branes and by two chromatographic techniques: gel filtra-
tion on Sepharose 4B (Sigma-Aldrich, Poland) followed
by cellulofine sulfate (Millipore, Billerica, USA) chroma-
tography [20]. The purification procedure afforded prepa-
rations of phages containing less than 5 U/ml endotoxin
for 109 pfu/ml (lysates: approx. 3000 U/ml), as deter-
mined by chromogenic Limulus amebocyte lysate assay
(QLC-1000 Chromogenic Endpoint LAL, Bio Whittaker,
USA). The phage concentrations were measured by the
double-layer method of Adams [21]. The batches pre-
pared by the Bacteriophage Laboratory of the IIET used
were: T4108, T4119, and HAP1112, all finally dialysed
against phosphate-buffered saline (PBS).
Lipopolysaccharide (LPS)
LPS was prepared at the IIET. Bacteria were grown for 48
h at 37°C in standard (0.5% NaCl) Luria-Bertani Broth
(LB) vigorously aerated by shaking. The bacteria were
killed with 0.5% phenol and centrifuged at 39,000 rpm
using a flow centrifuge (New Brunswick Scientific, USA)
[22]. The bacterial mass was washed three times with dis-
tilled water, lyophilised, treated with 90% phenol/water
(1:1), and heated to 65°C. LPS was extracted for 15 min
according to the method of Westphal and Jann [23]. The
extract was cooled to 4°C and centrifuged for 30 min at
3000 × g. The water phase was collected. Distilled water
was added to the remaining phenol phase and the extrac-
tion process was repeated. Both phases were dialysed
against water for 72 h (water phase) or for 120 h (phenol
phase) and lyophilised. To remove nucleic acids, the
resultant LPS was ultra-centrifugated (105,000 × g, 6 h,
repeated two times), and the LPS suspension was
lyophilised again. For the tests, 1 μg/ml of LPS suspension
in PBS was prepared by sonication (30 s). The activity of
LPS was determined by chromogenic Limulus amebocyte
lysate assay (QLC-1000 Chromogenic Endpoint LAL, Bio
Whittaker, USA) and it was defined as 4 × 104 U/ml in the
1-μg/ml preparation. The residual LPS in the bacteri-
ophage preparations allowed a final concentration in the
migration assay of 10 U/ml, which equals 0.25 ng/ml. The
LPS sample was diluted with PBS to the various desired
concentrations (dose gradient); the control for the phage
preparations was 10 U/ml.
Tumour cells
The B16 mouse melanoma cell line and the Hs294T
human melanoma cell line were obtained from the ATCC
(Rockville, Maryland, USA.). The lines are maintained at
the Cell Culture Collection at IIET.
The cells were cultured with normal foetal bovine serum
(FBS) media. One day before the migration, the medium
was changed: (i) Hs294T was cultured again with medium
containing FBS before both fibronectin and matrigel
migration and (ii) B16 was cultured in medium contain-
ing FBS before the fibronectin migration assay, but in Dul-
becco's modified Eagle's medium (DMEM) before the
matrigel migration assay as its migration activity was poor
and the FBS deficiency stimulated the cells' response to
FBS attraction in the migration assay. Before the assay,
cells were collected with non-enzymatic Cell Dissociation
Solution (Sigma-Aldrich, Poland), centrifuged, resus-
pended in DMEM (with no FBS), counted in a Burker
counting chamber (Roth, Germany) in light microscopy
with trypan, and diluted to the desired concentration. The
cells were used immediately in the migration assay.
Migration chamber preparation
Fibronectin assay: 8-μm insert membranes (Falcon BD
Biosciences, USA) were sterilely covered with fibronectin
(100 μg/ml, Falcon BD Biosciences). Both sides of the
membrane were covered with 20 μl of the fibronectin sus-
pension and incubated for 30 min at 37°C. Fibronectin
was removed and the inserts were washed three times with
sterile water. Subsequently, both sides of the membrane
were immersed in a 0.1% albumin solution and incu-
bated for 15 min. The inserts were washed three times
with sterile water and dried. The prepared inserts were not
stored, but used immediately after preparation.
Matrigel assay: according to the manufacturer's instruc-
tions, the 8-μm insert membranes (Falcon BD Bio-
sciences) were covered with matrigel diluted 1:4 with
DMEM under sterile conditions, with cooling. Only the
upper side of the membrane was covered with 10 μl of the
matrigel suspension (i.e. approx. 7 μg/cm2 of the mem-
brane) and slowly dried (overnight in a covered plate) at
37°C. Such prepared inserts can be stored at -20°C. If fro-
zen, they were defrosted at 37°C, and rehydrated with
DMEM for 2 hours, and directly applied in the migration
assay.BMC Microbiology 2009, 9:13 http://www.biomedcentral.com/1471-2180/9/13
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Migration assay
The cells were suspended in DMEM with no FBS, and
applied to the upper section of the migration chamber,
with 1 × 105 Hs294T cells/insert in both the fibronectin
and the matrigel assay, 4 × 105 B16 cells/insert in the
matrigel assay, and 5 × 105 B16 cells/insert in the fibronec-
tin assay. All preparations (bacteriophages, LPS, PBS basic
control) were correlated and added at the same final vol-
umes of PBS (125–135 μl), both in the upper and the
lower sections of the migration chamber. All the prepara-
tions and cells in the upper section were completed with
DMEM and with FBS-containing medium to 0.5 ml in the
lower section (according to the manufacturer's instruc-
tions). Final concentrations of the bacteriophage prepara-
tions were 1.5–2.5 × 109 pfu/ml containing 10 U/ml
residual LPS. Concentration of the attracting agent, FBS, in
the lower section of the migration chamber was 7.3–
7.5%.
The migration was carried out at 37°C with CO2. The time
of migration was initially optimised and was 2 h for B16
on fibronectin, 7–8 h for B16 on matrigel, 1 h 20 min for
Hs294T on fibronectin, and 4.5–5 h for Hs294T on
matrigel. After this time (following the manufacturer's
instructions) the cells from the upper side of the mem-
brane were removed with a cotton swab. The cells on the
bottom side of the membrane were fixed and stained with
a Diff-Quick Set (Medion Diagnostics, Düdingen, Switzer-
land) and counted by light microscopy. The number of
cells per membrane was determined, accumulated into
groups, and the average was presented.
Statistical methods
One-way analysis of variance (ANOVA) and the Kruscal-
Wallis test with the Statistica 8.0 software package were
applied http://www.statsoft.pl.
Results
The migration of human and mouse melanoma on 
fibronectin
Fibronectin is one of the ECM proteins. Its primary func-
tion is cell adhesion to the ECM, which is mediated by
fibronectin's RGD sequences, and engagement of specific
cell surface receptors. It may involve the probable mecha-
nisms of phage action, so the migration studies were initi-
ated with this protein.
The migration assay of B16 melanoma with the bacteri-
ophage preparations and LPS revealed marked and statis-
tically significant inhibition of migration by both T4
phage and HAP1 phage, which was almost the same for
both bacteriophages. Migration was inhibited by 34% (p
= 0.0235) and 36% (0.0164), respectively, compared with
the control and by 42% (p = 0.0008) and 44% (0.0006),
respectively, compared with 10 U/ml LPS, identical to the
residual LPS content in the phage preparations (Fig. 1).
No effect on migration was induced by 10 U/ml LPS (Fig.
1). A gradient of LPS concentrations (0.2–20 U/ml) also
did not show any effect on B16 migration activity (Fig. 2).
The migration assay of Hs294T melanoma with bacteri-
ophage preparations and LPS revealed response similar to
that of the mouse melanoma. Human melanoma was not
stimulated by 10 U/ml LPS (the activity was identical to
that of the PBS control). Its migration was decreased by
31% (p = 0.0423) by T4 compared with PBS. A significant
difference between PBS and HAP1 was not observed
(28%, p = 0.0859) (Fig. 3). Expanded analysis of the effect
of LPS (dose gradient) showed no significant or marked
trend in the human melanoma response (Fig. 4).
Migration of human and mouse melanoma on matrigel 
matrix
Matrigel matrix is a reconstituted basement membrane
with a wider range of components, including stimulating
and regulating factors and various proteins. It allows more
complex and multiple interactions of cells during their
motility and more complete analysis of the migration
process.
The overall migration activity of B16 melanoma was poor
and the results were strongly dispersed. Therefore the
The effect of T4 and HAP1 bacteriophages on B16 mouse  melanoma migration on fibronectin Figure 1
The effect of T4 and HAP1 bacteriophages on B16 
mouse melanoma migration on fibronectin. The 
insert: an 8-μm 0.3-cm2 membrane was covered with 
fibronectin. B16 melanoma cells were applied at 5 × 105 cells 
per insert in DMEM. The final concentrations of the bacteri-
ophage preparations were 1.5–2.5 × 109 pfu/ml and 10 U/ml 
of residual LPS. The LPS control was also 10 U/ml (which 
equals 0.25 ng/ml). The concentration of the attracting agent 
FBS in the lower section of the migration chamber was 7.3–
7.5%. Migration was carried out for 2 h at 37°C in CO2. The 
cells were stained and counted under light microscopy on 
the whole membrane. The mean number of cells per mem-
brane (bars) and SD (lines) are presented.BMC Microbiology 2009, 9:13 http://www.biomedcentral.com/1471-2180/9/13
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The effect of LPS on B16 mouse melanoma migration on  fibronectin Figure 2
The effect of LPS on B16 mouse melanoma migra-
tion on fibronectin. The insert: an 8-μm 0.3-cm2 mem-
brane was covered with fibronectin. B16 melanoma cells 
were applied at 5 × 105 cells per insert in DMEM. LPS was 
applied as a dose gradient (10 U/ml, equal to 0.25 ng/ml). The 
concentration of the attracting agent FBS in the lower sec-
tion of the migration chamber was 7.3–7.5%. Migration was 
carried out for 2 h at 37°C in CO2. The cells were stained 
and counted under light microscopy on the whole mem-
brane. The mean number of cells per membrane (bars) and 
SD (lines) are presented.
The effect of T4 and HAP1 bacteriophages on Hs294T  human melanoma migration on fibronectin Figure 3
The effect of T4 and HAP1 bacteriophages on 
Hs294T human melanoma migration on fibronectin. 
The insert: the 8-μm 0.3-cm2 membrane was covered with 
fibronectin. Hs294T melanoma cells were applied at 1 × 105 
cells per insert in DMEM. The final concentrations of the bac-
teriophage preparations were 1.5–2.5 × 109 pfu/ml and 10 U/
ml of residual LPS. The LPS control was also 10 U/ml (which 
equals 0.25 ng/ml). The concentration of the attracting agent, 
FBS, in the lower section of the migration chamber was 7.3–
7.5%. Migration was carried out for 1 h 20 min at 37°C in 
CO2. The cells were stained and counted under light micros-
copy on the whole membrane. The mean number of cells per 
membrane (bars) and SD (lines) are presented.
The effect of LPS on Hs294T human melanoma migration on  fibronectin Figure 4
The effect of LPS on Hs294T human melanoma 
migration on fibronectin. The insert: the 8-μm 0.3-cm2 
membrane was covered with fibronectin. Hs294T melanoma 
cells were applied at 1 × 105 cells per insert in DMEM. LPS 
was applied as a dose gradient (10 U/ml equals 0.25 ng/ml). 
The concentration of the attracting agent FBS in the lower 
section of the migration chamber was 7.3–7.5%. Migration 
was carried out for 1 h 20 min at 37°C in CO2. The cells 
were stained and counted under light microscopy on the 
whole membrane. The mean number of cells per membrane 
(bars) and SD (lines) are presented.
The effect of T4 and HAP1 bacteriophages on B16 mouse  melanoma migration on matrigel matrix Figure 5
The effect of T4 and HAP1 bacteriophages on B16 
mouse melanoma migration on matrigel matrix. The 
insert: the 8-μm 0.3-cm2 membrane was covered with 
matrigel (approx. 7 μg/cm2). B16 melanoma cells were 
applied at 4 × 105 cells per insert in DMEM. The final concen-
trations of the bacteriophage preparations were 1.5–2.5 × 
109 pfu/ml and 10 U/ml of residual LPS. The LPS control was 
also 10 U/ml (which equals 0.25 ng/ml). The concentration of 
the attracting agent FBS in the lower section of the migration 
chamber was 7.3–7.5%. Migration was carried out for 7–8 h 
at 37°C in CO2. The cells were stained and counted under 
light microscopy on the whole membrane. The mean number 
of cells per membrane (bars) and SD (lines) are presented.BMC Microbiology 2009, 9:13 http://www.biomedcentral.com/1471-2180/9/13
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assay did not show a significant inhibition of B16 migra-
tion by T4 and HAP1 (Fig. 5). The LPS concentration gra-
dient did not reveal any significant trend towards
stimulation or inhibition related to the dose series,
although the test was made with two complementary sets
of doses. The dispersion of the results was also remarka-
ble, which strongly hindered their analysis (Figs. 6 and 7).
The migration assay of Hs294T melanoma with the bacte-
riophage preparations and LPS revealed an inhibition of
migration by HAP1 phage by 48% (p = 0.0407). A signif-
icant difference between PBS and T4 was not observed
(38%, p = 0.0859). Human melanoma migration was not
affected by 10 U/ml LPS (Fig. 8). Expanded analysis of the
LPS effect (dose gradient) also showed no effect on
Hs294T cell response (Fig. 9).
Discussion
The most important question of this study was the gen-
eral effect of the bacteriophage preparations on
melanoma's migration activity, mostly because of the
perspective of developing bacteriophage therapy. The
migration of human and mouse melanoma can be inhib-
ited by the purified T4 and HAP1 bacteriophage prepara-
tions with no stimulative action, which is plainly an
advantageous effect. A response of melanoma cells to
LPS (within the investigated range) was not observed
and the differences from those of the bacteriophage
preparations were marked, so the antimigration activity
of the studied preparations cannot be attributed to LPS.
It should be pointed out that the LPS content in the puri-
fied phage preparation was minimal; in this study the
final concentration was 0.25 ng/ml (10 U/ml by the
chromogenic Limulus amoebocyte lysate assay).
The high variability of the assay hindered analysis of the
observations. The more general assay with matrigel was
also much more variable and it ascertained only an
inhibitory effect of HAP1 on Hs294T migration. In the
fibronectin assay, significant inhibition was observed
both for the mouse (T4 and HAP1) and human (T4)
melanoma. This is in line with the hypothesis on the
RGD-engaging mechanism of changes in cell migration
[15] as cell adhesion to the ECM is mediated by fibronec-
tin's RGD sequences. Integrins alpha(v)beta(3),
alpha(IIb)beta(3), and alpha(5)beta(1) mediate cancer
cell motility and adhesion and are susceptible to the
activity of RGD homologues. They are known to pro-
mote metastasis and malignancy and to be highly
expressed in melanoma cells (in contrast to normal
melanocytes). Alpha(v)beta(3) and beta(1)-integrins are
highly expressed at the leading edge of invasive explants.
They also regulate MMPs functions that are critical for
the invasive properties of tumour cells as they degrade
ECM components [18,19]. The overall mechanism of
melanoma motility is obviously complex and engages a
The effect of low doses of LPS on B16 mouse melanoma  migration on matrigel matrix Figure 6
The effect of low doses of LPS on B16 mouse 
melanoma migration on matrigel matrix. The insert: 
the 8-μm 0.3-cm2 membrane was covered with matrigel 
(approx. 7 μg/cm2). B16 melanoma cells were applied at 4 × 
105 cells per insert in DMEM. LPS was applied as a dose gra-
dient (10 U/ml equals 0.25 ng/ml). The concentration of the 
attracting agent FBS in the lower section of the migration 
chamber was 7.3–7.5%. Migration was carried out for 7–8 h 
at 37°C in CO2. The cells were stained and counted under 
light microscopy on the whole membrane. The mean number 
of cells per membrane (bars) and SD (lines) are presented.
The effect of LPS on B16 mouse melanoma migration on  matrigel matrix Figure 7
The effect of LPS on B16 mouse melanoma migra-
tion on matrigel matrix. The insert: the 8-μm 0.3-cm2 
membrane was covered with matrigel (approx. 7 μg/cm2). 
B16 melanoma cells were applied at 4 × 105 cells per insert in 
DMEM. LPS was applied as a dose gradient (10 U/ml equals 
0.25 ng/ml). The concentration of the attracting agent FBS in 
the lower section of the migration chamber was 7.3–7.5%. 
Migration was carried out for 7–8 h at 37°C in CO2. The 
cells were stained and counted under light microscopy on 
the whole membrane. The mean number of cells per mem-
brane (bars) and SD (lines) are presented.BMC Microbiology 2009, 9:13 http://www.biomedcentral.com/1471-2180/9/13
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wider range of surface particles. Other factors strongly
associated with melanoma development and progres-
sion that also play roles in melanoma adhesion and
motility are melanoma cell adhesion molecule (Mel-
CAM, MUC18, CD146), L1 cell adhesion molecule (L1-
CAM, CD171), activated leukocyte cell adhesion mole-
cule (ALCAM, CD166), vascular cell adhesion molecule
1 (VCAM-1, CD106), intracellular cell adhesion mole-
cule 1 (ICAM-1, CD54), and carcinoembryonic antigen-
related cell adhesion molecule 1 (CEACAM1, CD66a)
[19]. One cannot preclude unknown functions of the
above factors in the inhibitory action of T4-like phage
preparations on melanoma migration. Nevertheless, cur-
rent knowledge (both laboratory observations and theo-
retical analyses) does not justify any assumptions
regarding their interaction with bacteriophages. Some of
the above surface particles interact via beta(3)-integrin
subunits; for example, L1-CAM mediates melanoma
cell/melanoma cell and melanoma cell/endothelial cell
interactions [24]. Therefore, L1-CAM can be indirectly
engaged in the studied effect. We consider the problem
of molecular mechanisms of phage-melanoma interac-
tion still open and believe that further investigations are
needed.
Models of in vitro studies allow investigating the direct
effects of preparations on migrating cells. This brings us
closer to understanding previously observed in vivo
antimetastatic effects [13,14]. The in vivo anticancer
effects may result from an impact of the investigated
preparations on immunological systems, which has to
be seriously considered. In vitro migration excludes the
effect of complex mammalian immunology. Observa-
tions of the "antimigratory" effect of bacteriophages sug-
gest that they are able to influence (at least some) cancer
cells directly. Previously we investigated the interactions
of bacteriophage T4 with mammalian cells, observing an
unexpected ability of the bacteriophage to bind weakly
to melanoma cells in vitro. We selected bacteriophage
HAP1, which was able to bind cancer cells more strongly.
Importantly, HAP1 was also much more effective against
melanoma metastases in vivo [13]. A mutation in the hoc
gene that differentiates bacteriophage HAP1 and its
parental strain T4 was found [14]. Nevertheless, in these
studies we did not find any difference in the effects of T4
and HAP1 on melanoma migration in vitro. This may
suggest that some immunological components are
engaged in the activity of HAP1. This phage is different
(from T4 phage) in, among other properties, the time
and means of clearance from a mammalian organism,
which may contribute to these observations. On the
other hand, the difference between T4 and HAP1 interac-
The effect of T4 and HAP1 bacteriophages on Hs294T  human melanoma migration on matrigel matrix Figure 8
The effect of T4 and HAP1 bacteriophages on 
Hs294T human melanoma migration on matrigel 
matrix. The insert: the 8-μm 0.3-cm2 membrane was cov-
ered with matrigel (approx. 7 μg/cm2). Hs294T melanoma 
cells were applied at 1 × 105 cells per insert in DMEM. The 
final concentrations of the bacteriophage preparations were 
1.5–2.5 × 109 pfu/ml and 10 U/ml of residual LPS. The LPS 
control was also 10 U/ml (which equals 0.25 ng/ml). The con-
centration of the attracting agent FBS in the lower section of 
the migration chamber was 7.3–7.5%. Migration was carried 
out for 4.5–5 h at 37°C in CO2. The cells were stained and 
counted under light microscopy on the whole membrane. 
The mean number of cells per membrane (bars) and SD 
(lines) are presented.
The effect of LPS on Hs294T human melanoma migration on  matrigel matrix Figure 9
The effect of LPS on Hs294T human melanoma 
migration on matrigel matrix. The insert: the 8-μm 0.3-
cm2 membrane was covered with matrigel (approx. 7 μg/
cm2). Hs294T melanoma cells were applied at 1 × 105 cells 
per insert in DMEM. LPS was applied as a dose gradient (10 
U/ml equals 0.25 ng/ml). The concentration of the attracting 
agent FBS in the lower section of the migration chamber was 
7.3–7.5%. Migration was carried out for 4.5–5 h at 37°C in 
CO2. The cells were stained and counted under light micros-
copy on the whole membrane. The mean number of cells per 
membrane (bars) and SD (lines) are presented.BMC Microbiology 2009, 9:13 http://www.biomedcentral.com/1471-2180/9/13
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tions with melanomas may simply be undetectable in
the types of tests conducted.
We believe that our observations are of importance for
any further attempts to use bacteriophage preparations
in antibacterial treatment. To the best of our knowledge,
there are no published data on the effect of bacteri-
ophages on macrophage or lymphocyte (normal cell)
migration in vitro. We also work on this issue and we
hope to be able to present data in the future. It should be
pointed out that bacteriophages constitute a strongly
diversified group of microorganisms and our observa-
tions apply to T4-like phages. Other types of bacteri-
ophages (with different genetics and protein
construction) must be investigated and analysed inde-
pendently. As the risk of antibiotic-resistant hospital
infections strongly affects cancer patients, we consider
that such investigations are greatly needed. We also
believe that they will contribute to the general under-
standing of bacteriophage biology. Bacteriophages,
extremely ubiquitous entities, are in permanent contact
with human organisms. They are present in water, food,
and soil and constitute a part of the "microbial flora" of
human skin and gastrointestinal tract and penetrate all
tissues. Knowledge about their influence on the human
body may be very useful, similar to the knowledge about
the "beneficial" strains of bacteria that make up our
microflora. There may also be some "beneficial" bacteri-
ophages in our bodies and in our environment.
Conclusion
The migration of human and mouse melanoma can be
inhibited by purified T4 and HAP1 bacteriophage prepa-
rations. A response of melanoma cells to LPS (within the
investigated range) was not observed, so the antimigra-
tion activity of the studied preparations cannot be attrib-
uted to LPS. No differences in the effects of T4 and HAP1
on melanoma migration were observed.
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